What does 98.2% purity on a C18 column actually tell me about an ecnoglutide vial?

Setup, so nobody has to ask: 98.2% · a C18 column · ecnoglutide.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

How should I read this, and where are the traps?

It tells you 98.2 per cent of the integrated area came off a C18 column where ecnoglutide comes off, and the remaining 1.8 per cent did not. That is an area statement at one wavelength, not a mass statement about the vial: 1.8 per cent of area is only 1.8 per cent of mass if every impurity absorbs exactly as strongly as the parent, which none of them do. It also says nothing about how many milligrams are in the glass — water, counter-ion and a short fill are all invisible to it. What a C18 column does add is a constraint on what could be hiding: a column that retains by hydrophobicity separates deletion sequences well and separates isomers of identical hydrophobicity not at all.

In practice, reverse-phase HPLC is the workhorse for peptide purity work, but it is almost universally run under conditions that are not optimal for a peptide of this chain length.

Trifluoroacetic acid at 0.1 per cent is the standard ion-pairing agent because it suppresses tailing by neutralising the basic residues, but it also suppresses mass spectrometry signal.

The underlying point is that system suitability checks on replicate injections of a known standard establish whether the method was in control — if the peak area varies by more than two per cent between replicates, something is wrong.

The resolving power of a separation is quantified by the resolution parameter R, defined from the heights and widths of adjacent peaks, and pharmacopoeial methods typically demand R greater than 1.5 for a method to be considered validated.

Ask for the chromatogram and the system suitability data, not just the number.

edited 19 Sept 2024 by g_paskevicius — added the citation requested in comments

Mechanically, the limit of this technique for these molecules is reaching a point where small improvements require proportionally large investments in method development.

Temperature affects both the viscosity of the mobile phase and the dynamics of molecular interactions, and a method developed at 25 degrees and run at 40 degrees will not behave identically.

More usefully, wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.

Inter-laboratory studies using identical methods on identical material show precision well within half a per cent when the method is locked down, pointing to method variability as the primary source of disagreement.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

Start by understanding what the detector is measuring and what that means about how the molecule needs to be prepared and handled before injection.

Proline-rich sequences are particularly problematic because the isomerisation kinetics are in the same timescale as the separation, leading to split or broadened peaks at low temperature.

Sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.

The limitation is that co-elution is invisible — if two species happen to have the same retention time, they will report as a single peak at their combined area.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

The most important parameter is the one that is almost never specified: the gradient slope during the region where your main peak elutes.

The 214 nanometre wavelength is chosen because it corresponds to the amide backbone absorption, making response roughly proportional to the number of peptide bonds.

The selectivity of a reverse-phase separation depends on the hydrophobicity of the side-chain profile, which is why two peptides can co-elute even if they differ by a residue.

The caveat is that HPLC is a purity technique and says almost nothing about whether the main peak is actually your target compound — that is why identity confirmation from mass spectrometry or peptide mapping matters.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

High-performance liquid chromatography is a separation technique, not an identification technique, and it answers the question "how much of the detected signal is a single species" not "which species is it."

Detector linearity is why a heavily loaded peak can give false purity by compressing the main peak height while leaving impurity shoulders unchanged.

Peptide separation by reverse-phase high-performance liquid chromatography is described in the general chapters of the United States Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia, and the methods converge on essentially the same principles.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.